HORIBA FRANCE SAS

Their core work

HORIBA France is the European arm of the HORIBA Group, a global leader in analytical and measurement instruments. In H2020 projects, they contribute advanced spectroscopy, optical diagnostics, and nanoparticle characterization capabilities — acting as the instrumentation partner that provides the measurement tools other consortium members need. Their work spans from Raman spectroscopy for cancer diagnosis to emission measurement systems for nanoparticles, consistently sitting at the intersection of precision instrumentation and applied science.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), HORIBA France focused on advanced materials characterization — graphene, layered materials, and nanoparticle emission measurement — reflecting their core instrumentation business. From 2018 onward, their portfolio shifted toward two distinct directions: energy materials (solid-state batteries, thermoelectrics, nanoionics via HARVESTORE) and medical photonics (cancer diagnostics via PHAST). This dual pivot suggests the company is strategically applying its measurement expertise to higher-value application domains rather than staying in pure materials science.

HORIBA France is moving from general-purpose instrumentation toward application-specific measurement solutions in healthcare diagnostics and energy storage — expect continued growth in clinical and IoT sensing.

How they like to work

HORIBA France never coordinates projects — they join as a specialist partner providing measurement and instrumentation capabilities that other consortium members lack. With 249 unique partners across 26 countries, they operate as a highly networked contributor rather than a project leader, plugging into diverse consortia wherever advanced analytical tools are needed. This makes them a low-friction partner: they bring equipment and expertise without competing for scientific leadership.

Exceptionally broad network for a company with only 7 projects: 249 unique consortium partners across 26 countries, largely driven by participation in flagship initiatives like Graphene Core1. Their reach is pan-European with no strong geographic concentration.

What sets them apart

HORIBA France bridges the gap between research-grade instrumentation and real-world measurement challenges. Unlike academic partners who develop measurement concepts, or SMEs who build niche sensors, HORIBA brings industrially proven spectroscopy and optical platforms that can be adapted within a project and then scaled commercially. For consortium builders, they offer a rare combination: the reliability and equipment base of a large corporation with the technical depth to co-develop new measurement methods.

Highlights from their portfolio

• ULTRAPLACAD
  Largest single funding (EUR 646,922) — plasmonic biosensors for early cancer diagnosis, showing HORIBA's capacity to contribute substantially to medical device development.
• HARVESTORE
  Marks a strategic pivot into energy harvesting and IoT, covering solid-state batteries, thermoelectrics, and fuel cells — a significant departure from their traditional instrumentation focus.
• PHAST
  Most recent project (2020–2025), combining Raman spectroscopy with multimodal imaging for cancer therapy — signals HORIBA's current direction in clinical photonics.